The Lancet Renames 1-in-8 Women’s PCOS to PMOS as Experts Stress Whole-Body Risks
Updated
Updated · UKNow · May 31
The Lancet Renames 1-in-8 Women’s PCOS to PMOS as Experts Stress Whole-Body Risks
8 articles · Updated · UKNow · May 31
The Lancet has redesignated polycystic ovarian syndrome as polyendocrine metabolic ovarian syndrome, saying the old name wrongly centered ovarian cysts rather than the disorder’s broader endocrine and metabolic effects.
One in eight women live with the condition, which clinicians say can span irregular periods, fertility problems, acne and excess hair growth, insulin resistance, type 2 diabetes risk, high cholesterol, high blood pressure and mental health impacts.
Diagnostic criteria are unchanged for now—providers will still assess menstrual irregularities, ultrasound findings and elevated androgens—but the new terminology is meant to prompt earlier recognition and more comprehensive evaluation.
A multi-year rollout is expected as medical coding, insurance systems and electronic health records are updated, following years of research and patient advocacy that pushed for a name reflecting the condition’s multisystem nature.
Will the PCOS name change to PMOS finally shift treatment from fertility to the entire metabolic and endocrine disorder?
It took 14 years to rename this condition. What does this reveal about the systemic challenges in women's healthcare?
Beyond a new name, can new diagnostic models truly end the years-long wait for a PMOS diagnosis for millions?